By Megan Martin, Communications Manager
In an effort to advance oncology care available to patients in the Middle East and North Africa (MENA) region, the NCCN has announced the establishment of the MENA Coordinating Office for NCCN Collaboration. The office, located on the King Abdubazig Medied City in Riyadh, Saudi Arabia will serve to coordinate activities relating to current NCCN programs in MENA as well as the development of future initiatives.
"The MENA Coordinating Office for NCCN Collaboration will be integral to the betterment of patient care in the region through implementation of our expert-developed, evidence-based recommendations for oncology management," said William T. McGivney, PhD, CEO of NCCN.
NCCN has held two educational MENA Congresses in the United Arab Emirates. The first was held in Al Ain and the second in Abu Dhabi. These multiple-disease oncology congresses have served to establish collegial discussion on influential data that support recommendations in specific NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™).
JNCCN — Journal of the National Comprehensive Cancer Network recently published a supplement, "The Abu Dhabi Declaration: Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region," that details discussions on clinical care for six tumor types and one on supportive care. This manuscript emphasizes issues in the management of breast, colon, hepatobiliary, non-small cell lung, and prostate cancers, as well as treatment of lymphomas and palliative care among the 16 countries considered.
To further understand the needs of clinicians in the MENA region, NCCN recently conducted an NCCN Trends™ Survey with NCCN.org registrants in the area. Oncology professionals responded from Algeria, Egypt, Iran, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, United Arab Emirates, and Yemen. Nearly 82 percent of the survey respondents are practicing physicians representing different cancer specialties. Notably, 78 percent claimed to frequently use NCCN Guidelines™ to direct their treatment of patients with cancer, with the majority indicating that they use them very frequently for this purpose. Treatment with drugs and biologics was the most prominent reason cited for accessing the NCCN Guidelines.NCCN plans to continue work with its clinical colleagues in the MENA region to provide exceptional resources for education and to foster productive and collaborative professional relationships that will ultimately benefit patients with cancer in the area. For additional information on NCCN International Programs, visit NCCN.org/international.